MX2019006676A - Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia. - Google Patents
Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia.Info
- Publication number
- MX2019006676A MX2019006676A MX2019006676A MX2019006676A MX2019006676A MX 2019006676 A MX2019006676 A MX 2019006676A MX 2019006676 A MX2019006676 A MX 2019006676A MX 2019006676 A MX2019006676 A MX 2019006676A MX 2019006676 A MX2019006676 A MX 2019006676A
- Authority
- MX
- Mexico
- Prior art keywords
- scleroderma
- treatment
- ccl2
- ccl2 antibodies
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención proporciona, entre otras cosas, anticuerpos anti- CCL2 mejorados caracterizados con alta afinidad, potencia, selectividad de tejido y/o especificidad de epítope, y usos de los mismos en particular, para el tratamiento de esclerodermia y enfermedades, trastornos y afecciones fibróticas y/o inflamatorias relacionadas. En algunas modalidades, la presente invención proporciona métodos y composiciones para el tratamiento de esclerodermia y enfermedades, trastornos afecciones fibróticas y/o inflamatorias relacionadas basados en un anticuerpo anti-CCL2 que tiene una afinidad de 10¯¹² M o mayor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650149P | 2012-05-22 | 2012-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006676A true MX2019006676A (es) | 2019-08-21 |
Family
ID=49624311
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014290A MX2014014290A (es) | 2012-05-22 | 2013-05-22 | Anticuerpos anti - ccl2 para el tratamiento de la esclerodermia. |
MX2019006676A MX2019006676A (es) | 2012-05-22 | 2014-11-21 | Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014014290A MX2014014290A (es) | 2012-05-22 | 2013-05-22 | Anticuerpos anti - ccl2 para el tratamiento de la esclerodermia. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20150158942A1 (es) |
EP (1) | EP2852411A4 (es) |
JP (2) | JP2015520768A (es) |
CN (2) | CN104487091A (es) |
AU (2) | AU2013266340A1 (es) |
BR (1) | BR112014029013A2 (es) |
CA (1) | CA2874031A1 (es) |
EA (1) | EA201491957A1 (es) |
HK (2) | HK1208825A1 (es) |
IN (1) | IN2014DN09951A (es) |
MX (2) | MX2014014290A (es) |
WO (1) | WO2013177264A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015029300A2 (pt) * | 2013-05-23 | 2017-09-19 | Shire Human Genetic Therapies | Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit |
US20160340414A1 (en) | 2014-01-15 | 2016-11-24 | Medimmune, Llc | Rsv-specific antibodies and functional parts thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2637801T3 (es) * | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
AU2002357770B2 (en) * | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
RS89204A (en) * | 2002-04-10 | 2006-12-15 | Applied Research Systems Ars Holding N.V. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
US8114964B2 (en) * | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
PA8675801A1 (es) * | 2005-05-19 | 2006-12-07 | Centocor Inc | Anticuerpos anti-mcp-1, composiciones, metodos y usos |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
US20100074886A1 (en) * | 2006-10-05 | 2010-03-25 | Anuk Das | Ccr2 antagonists for treatment of fibrosis |
-
2013
- 2013-05-22 CN CN201380038785.5A patent/CN104487091A/zh active Pending
- 2013-05-22 US US14/403,025 patent/US20150158942A1/en not_active Abandoned
- 2013-05-22 CN CN201610204124.0A patent/CN105854015A/zh active Pending
- 2013-05-22 BR BR112014029013A patent/BR112014029013A2/pt not_active Application Discontinuation
- 2013-05-22 MX MX2014014290A patent/MX2014014290A/es unknown
- 2013-05-22 IN IN9951DEN2014 patent/IN2014DN09951A/en unknown
- 2013-05-22 JP JP2015514149A patent/JP2015520768A/ja active Pending
- 2013-05-22 WO PCT/US2013/042196 patent/WO2013177264A1/en active Application Filing
- 2013-05-22 EP EP13794678.6A patent/EP2852411A4/en not_active Ceased
- 2013-05-22 AU AU2013266340A patent/AU2013266340A1/en not_active Abandoned
- 2013-05-22 CA CA2874031A patent/CA2874031A1/en not_active Abandoned
- 2013-05-22 EA EA201491957A patent/EA201491957A1/ru unknown
-
2014
- 2014-11-21 MX MX2019006676A patent/MX2019006676A/es unknown
-
2015
- 2015-09-30 HK HK15109636.4A patent/HK1208825A1/xx unknown
- 2015-09-30 HK HK15109600.6A patent/HK1208819A1/xx unknown
-
2016
- 2016-01-29 US US15/010,900 patent/US20160289319A1/en not_active Abandoned
-
2017
- 2017-08-04 JP JP2017151434A patent/JP2017193588A/ja active Pending
- 2017-09-12 US US15/702,206 patent/US20180179275A1/en not_active Abandoned
-
2018
- 2018-02-05 AU AU2018200834A patent/AU2018200834A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN105854015A (zh) | 2016-08-17 |
US20150158942A1 (en) | 2015-06-11 |
IN2014DN09951A (es) | 2015-08-14 |
EA201491957A1 (ru) | 2015-04-30 |
US20160289319A1 (en) | 2016-10-06 |
EP2852411A1 (en) | 2015-04-01 |
JP2017193588A (ja) | 2017-10-26 |
EP2852411A4 (en) | 2016-01-13 |
CN104487091A (zh) | 2015-04-01 |
HK1208825A1 (en) | 2016-03-18 |
AU2013266340A1 (en) | 2014-12-04 |
JP2015520768A (ja) | 2015-07-23 |
HK1208819A1 (en) | 2016-03-18 |
WO2013177264A1 (en) | 2013-11-28 |
BR112014029013A2 (pt) | 2017-09-19 |
MX2014014290A (es) | 2015-05-12 |
US20180179275A1 (en) | 2018-06-28 |
AU2018200834A1 (en) | 2018-02-22 |
CA2874031A1 (en) | 2013-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3532B1 (ar) | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
MX2018001532A (es) | Anticuerpos anti-angptl8 y usos de estos. | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
MX364591B (es) | Antagonistas de il-33 y usos de estos. | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
PH12019500929A1 (en) | Anti il-33 antibodies and uses thereof | |
NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX2015012872A (es) | Anticuerpos anti-tau y metodos de uso. | |
MX2014012978A (es) | Regiones de anticuerpo modificado y sus usos. | |
EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
WO2014016702A3 (en) | Humanized forms of monoclonal antibodies to human gnrh receptor | |
AU2018279184A1 (en) | Anti-TrkB antibodies | |
MX2019006676A (es) | Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia. |